Literature DB >> 1525578

Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization.

K Frank-Raue1, F Raue, H J Buhr, G Baldauf, D Lorenz, R Ziegler.   

Abstract

In 14 patients with occult persisting medullary thyroid carcinoma, tumor tissue was removed by microsurgical reoperation in 13 of 14 patients. This resulted in biochemical improvement in all but 1 patient and biochemical cure in 3 patients (21%). The lateral compartment of the neck or the upper mediastinum was involved in all but 1 patient. Before microsurgical reoperation, selective venous catheterization (SVC) for serum sampling along with serum calcitonin (CT) determination was done and compared to other localization methods. Tumor tissue could be localized correctly by SVC in 89% (CT gradient 1.21-2.02), computed tomography in 38%, and ultrasound in 28%. In patients with an elevated CT level after initial surgery and clinically occult disease, SVC is recommended for localization of tumor tissue. The affected side of the neck should be reoperated on with microdissection of the central and lateral compartment of the neck and the upper mediastinum. With this procedure, the cure rate of reoperation in patients with persistent occult MTC can be improved.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525578     DOI: 10.1089/thy.1992.2.113

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  8 in total

1.  Long-term outcome of reoperations for medullary thyroid carcinoma.

Authors:  Elizabeth Fialkowski; Mary DeBenedetti; Jeffrey Moley
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

2.  Management of thyroid cancers.

Authors:  Devendra A Chaukar; Anuja D Deshmukh; Mitali R Dandekar
Journal:  Indian J Surg Oncol       Date:  2010-11-21

Review 3.  Molecular imaging of neuroendocrine tumors.

Authors:  Jorge A Carrasquillo; Clara C Chen
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

Review 4.  Surgical strategy for the treatment of medullary thyroid carcinoma.

Authors:  J B Fleming; J E Lee; M Bouvet; P N Schultz; S I Sherman; R V Sellin; K E Friend; M A Burgess; G J Cote; R F Gagel; D B Evans
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

5.  The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.

Authors:  Zairong Gao; Hans J Biersack; Samer Ezziddin; Timur Logvinski; Rui An
Journal:  J Cancer Res Clin Oncol       Date:  2004-08-05       Impact factor: 4.553

6.  Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery.

Authors:  Matthias Schott; Holger S Willenberg; Cornelia Sagert; Thi-Bang-Tam Nguyen; Sven Schinner; Mathias Cohnen; Kenko Cupisti; Claus F Eisenberger; Wolfram T Knoefel; Werner A Scherbaum
Journal:  Clin Endocrinol (Oxf)       Date:  2007-03       Impact factor: 3.478

7.  Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma.

Authors:  N Abdelmoumene; M Schlumberger; P Gardet; A Roche; J P Travagli; C Francese; C Parmentier
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

8.  Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging.

Authors:  G Pellegriti; S Leboulleux; E Baudin; N Bellon; C Scollo; J P Travagli; M Schlumberger
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.